• Efficacy Study of the DIAMOND System to Treat Type 2 Diabetes Mellitus

  NCT01529216

  CompletedInterventionalNot ApplicableUpdated Mar 16, 2016
• Study With GFT505 (80mg) Versus Placebo in Patients With Type 2 Diabetes Mellitus

  NCT01261494

  CompletedInterventionalPhase 2Updated Jul 13, 2011
• Comparing Self Monitored Blood Glucose (SMBG) to Continuous Glucose Monitoring (CGM) in Type 2 Diabetes

  NCT01237301

  CompletedInterventionalNot ApplicableUpdated Oct 17, 2018
• Digital Therapeutic Based Investigation to Improve Glycemic Control in Patients With Type 2 Diabetes and Residual Hyperglycemia on Stable Medical Therapy

  NCT05266625

  Unknown statusInterventionalNot ApplicableUpdated Oct 30, 2023
• The Use of Libre to Improve Metabolic Control and Reduce Reliance on Medication

  NCT04632849

  CompletedInterventionalNot ApplicableUpdated Oct 5, 2021
• A Study In Patients With Type 2 Diabetes Mellitus

  NCT00256867

  CompletedInterventionalPhase 3Updated Jul 2, 2018

ClinicalTrials.gov ID

NCT02079376

Lead Sponsor

MetaCure LimitedINDUSTRY

Overall Status

Unknown status

Study Type

Interventional

Phase

Not Applicable

Enrollment

45Estimated

Last Update Posted

Mar 16, 2016Estimated

Start Date

Nov 2013

Primary Completion Date

Dec 2016Estimated

Completion Date

Dec 2016Estimated

Official Title

The DIAMOND® for the Treatment of Type 2 Diabetes: Can Blood Triglycerides Level be the Predictor for Therapy Efficiency A Multicentre, Prospective, Semi-randomized Study

Brief Summary

Study to evaluate the efficacy of gastric stimulation (GCM) using the DIAMOND System in the improvement of glycemic control measured by changes in HbA1c.

Relationship between blood TG level and the GCM efficacy will be evaluated.

• Type 2 Diabetes

• DIAMOND System

Ages Eligible for Study

Adult (18-64)Older Adult (65+)

Sexes Eligible for Study

All

Accepts Healthy Volunteers

No

Eligibility Criteria

Inclusion Criteria:

• Male and female subjects 18 through 70 years of age
• Body mass index > 30 and < 45 (kg/m2)
• Type 2 diabetes duration of at least 6 months
• Type 2 diabetic subjects treated with oral anti-diabetic agents [Sulfonylurea, Metformin, thiazolinedione (TZD) or DPP-4 inhibitors]
• Stable anti-diabetic medications for at least 3 months prior to enrollment, six months for thiazolinedione (TZD)
• The subject has been under routine diabetes care of the investigator or another single physician that can supply a medical record for at least 6 months prior to enrollment
• HbA1c 7.3% and ≤ 9.5 % on Visit 1
• Stable HbA1c, defined as no significant change (variation ≤ 0.5%) between a historical value recorded in the subject's medical record within 3 months prior to enrollment and the HbA1c gathered on Visit 1.
• Fasting blood glucose >120 and < 350 mg/dl on Visit 1.
• Women with childbearing potential (i.e., not post-menopausal or surgically sterilized) must agree to use adequate birth control methods
• Stable weight, defined as no significant weight change (variation <3%) within three months prior to enrollment as documented in the subject's medical record. For the subject treated with thiazolinedione, stable weight within six months.
• If taking theses medication, sable anti-hypertensive and lipid-lowering medication for at least one month prior to enrollment
• If subject is under anti-depressant medication the treatment needs to be stable for at least six months prior to enrollment.
• Ability and willingness to perform required study and data collection procedures and adhere to operating requirements of the DIAMOND System
• Willingness to perform at least four (3) capillary blood glucose tests per day twice a week for the duration of the study
• Willingness to refrain from using prescription, over the counter or herbal weight loss products for the duration of the trial
• Alert, mentally competent, and able to understand and willing to comply with the requirements of the clinical trial, and personally motivated to abide by the requirements and restrictions of the clinical trial
• Able to provide voluntary informed consent

Exclusion Criteria:

• Insulin therapy in last 3 months
• Taking GLP-1 agonists or in the last 3 months before the enrollment
• Currently taking fibrates, nicotinamide and omega 3 fatty acids as antilipidemic treatment
• Subjects with an EF less than 35% or otherwise indicated for an ICD
• Taking medications known to affect gastric motility such as narcotics (chronic use) and anticholinergics/antispasmodics
• Experiencing severe and progressing diabetic complications (i.e. retinopathy not stabilized, nephropathy with macroalbuminuria)
• Prior wound healing problems due to staphylococcus or candida
• Diagnosed with past or current psychiatric condition that may impair his or her ability to comply with the study procedures
• Use of anti-psychotic medications
• Diagnosed with a eating disorder such as bulimia or binge eating
• Obesity due to an endocrine disorder (e.g. Cushing disease)
• Pregnant or lactating
• Diagnosed with impaired liver function (liver enzymes 3 times greater than normal)
• Any prior bariatric surgery
• Any history of pancreatitis
• Any history of peptic ulcer disease within 5 years of enrollment
• Diagnosed with gastroparesis
• Use of active medical devices (either implantable or external) such as ICD, pacemaker, drug infusion device, or neurostimulator (either implanted or worn). Subjects using an external active device who are able and willing to avoid use of the device during the study may be enrolled.
• Cardiac history that physician feels should exclude the subject from the study.
• Use of another investigator device or agent in the 30 days prior to enrollment
• A history of life-threatening disease within 5 years of enrollment
• Change in diabetic medication from between Visit 1 and Visit 3.
• Any additional condition(s) that in the Investigator's opinion would warrant exclusion from the study or prevent the subject from completing the study

Primary Purpose

Treatment

Allocation

Randomized

Interventional Model

Parallel Assignment

Masking

Double

Lead Sponsor

MetaCure LimitedINDUSTRY

48693729109